Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
about
Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancerA Review of Systemic Treatment in Metastatic Triple-Negative Breast CancerMolecular Imaging of Biomarkers in Breast CancerMeta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancerDisease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysisEGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.A Review of Modeling Approaches to Predict Drug Response in Clinical OncologySuggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.Time-dependent endpoints as predictors of overall survival in multiple myelomaSurrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.Incorporating clinical trial data into daily cancer care.Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.Validation of novel imaging methodologies for use as cancer clinical trial end-pointsRandomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial.Endpoints in phase II trials for advanced non-small cell lung cancer.Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasisMeasures of outcome in metastatic breast cancer: insights from a real-world scenarioIxabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies.Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer.TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group.Detecting an overall survival benefit that is derived from progression-free survivalStopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials.Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide.Markers for nutrition studies: review of criteria for the evaluation of markers.Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trialsIdentification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end pointsIn the end what matters most? A review of clinical endpoints in advanced breast cancer.Endpoints in advanced breast cancer: methodological aspects & clinical implications.Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trialsInternational guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy.Combination drug delivery approaches in metastatic breast cancerDetecting overall survival benefit derived from survival postprogression rather than progression-free survival.Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis.Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available EvidenceReview of meta-analyses evaluating surrogate endpoints for overall survival in oncology.The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy."New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapyProgression-free survival as a surrogate endpoint in advanced breast cancer
P2860
Q24202199-8F3D359A-FA56-472F-9379-7B0578A8ABFBQ26752846-60F3C90F-5253-42C5-86AE-1A9F1C4D4FACQ26772870-BB5D4DB8-9284-4FCE-87A2-64C5A07CC831Q26860469-A4926D79-BA4B-4B74-B512-CC5709E489FFQ26860637-1CD65214-13DA-45F7-8C83-6A1386F32571Q27851583-1F085450-68E8-4931-94B8-785373FCF696Q28066777-82171093-A229-4BF1-8595-70167E67E90FQ30437854-263DD593-E567-4F3A-9F45-79AD292F4F08Q30538040-019FCB83-1FE7-4C7B-8F70-418803D9C006Q30627447-E231B8C6-26F3-456A-91AA-0FC3EC25516CQ30836868-9C07AF6C-7CCF-4059-93EE-3556194CD5ADQ33382437-4ADFEE27-B8E9-47A8-B24A-47B504EE90E2Q33394106-B7AE07FF-8709-4EB9-A1E4-EA36C9ACC251Q33421880-04590A93-C38B-40F6-823F-910C61C2EDC6Q33557040-F6824B0A-8FE0-44A0-B1A6-9BFDC098867CQ33582678-8A8B7BDC-76DD-46C5-8FD6-E14334E50640Q33699649-4E3F0B02-74B2-4232-8410-F320DD806C78Q33762423-ABA3D470-9773-4B1B-B232-8EB5F48B6123Q33800697-6451CC84-EF02-4BAD-9C52-22468C51AD20Q33880656-218CD553-0BD3-4CA8-93BD-4EECCB641668Q34063143-1F46EA83-4018-48DF-B59B-8FD4857EA2E6Q34094103-6E361D85-494B-467E-A9DD-33B6856FFD92Q34132767-094A8497-F06E-4DC2-9996-4D4586A1E03BQ34364879-33E4B125-9631-4C15-B672-25CF68D9EABCQ34716556-406EA502-B6A6-475F-BACF-D4E0660B535DQ35004750-FF2551DC-8ADC-46F0-B2B5-EB53ED5207D2Q35584322-5069FB38-3A5A-4A6F-928B-900E3856953DQ35611036-0AA4BEA4-F9AF-404E-B211-7BEE9DF5E594Q35645254-4FF6314D-8CD8-4894-80DA-AB7B40CB6F1EQ35820247-C1642F6A-732F-467B-9F00-B2CF1DA08ACCQ35825822-9F15FEB8-1674-4DC3-BC79-DABD5C20407AQ35872691-81167864-5B0A-49C1-BDA7-FA79491172DFQ35955198-68DEFF7C-DE88-47EC-BBFF-C53F0CAD9A5EQ36173497-54646A47-7DC8-46E6-96CB-B486E82D7AB2Q36215439-598FBAB8-91EA-4639-B649-3A67B538E901Q36248498-577DF7D3-8AF9-449E-B166-88E5F5D8B00AQ36349459-9AC679F1-CE72-4A9E-81D8-83A3B8B59B2AQ36353287-7EA3069E-0511-46F5-B284-24E24068297DQ36361371-1AF892B5-BD5B-4C4C-A071-17796A16BCB1Q36552307-5FC1A895-DAFF-47A8-ACA5-07FE185AEDD0
P2860
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Evaluation of tumor response, ...... s in metastatic breast cancer.
@en
Evaluation of tumor response, ...... s in metastatic breast cancer.
@nl
type
label
Evaluation of tumor response, ...... s in metastatic breast cancer.
@en
Evaluation of tumor response, ...... s in metastatic breast cancer.
@nl
prefLabel
Evaluation of tumor response, ...... s in metastatic breast cancer.
@en
Evaluation of tumor response, ...... s in metastatic breast cancer.
@nl
P2093
P50
P356
P1476
Evaluation of tumor response, ...... ts in metastatic breast cancer
@en
P2093
George Sledge
Gul Atalay Basaran
Hans-Joachim Lück
Jacek Jassem
Jacques Bonneterre
James Carmichael
Jean-Marc Nabholtz
Marc Buyse
Marijke Bontenbal
Martine J Piccart-Gebhart
P304
P356
10.1200/JCO.2007.10.8407
P407
P577
2008-04-01T00:00:00Z